This inventor holds 3 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 2 EPO patents. Top assignees: Promethera Biosciences S.a./n.v., Promethera Therapeutics Sa. Active years: 2019-2022.
Company Filing History:
Years Active: 2019-2022
Title: Innovations by Inventor Kris Gellynck
Introduction
Kris Gellynck is an innovative inventor based in Saint-Gilles, Belgium. He has contributed significantly to the field of life sciences, particularly in the development of adult liver progenitor cells, earning him a total of three patents. His research has the potential to revolutionize treatments for liver diseases and enhance biomedical research.
Latest Patents
Kris Gellynck's most recent patents focus on a method for producing novel adult liver progenitor cells, known as H2Stem Cells. These cells have been characterized using a series of biological activities and markers. The methods he developed provide these cells in the form of adherent cells and three-dimensional cell clusters in suspension. This innovation enables differentiation into liver-specific cells that possess strong activities. Furthermore, these H2Stem Cells can be utilized for treating liver diseases or for evaluating the efficacy, metabolism, and toxicity of various compounds.
Career Highlights
Throughout his career, Kris Gellynck has been associated with prominent companies, including Promethera Biosciences and Promethera Therapeutics. His work at these organizations has enabled him to contribute to cutting-edge research in regenerative medicine and cellular therapies.
Collaborations
Kris has collaborated with notable individuals in his field, including Etienne Sokal and Sarah Snykers. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his research and innovations in the biomedical sector.
Conclusion
Kris Gellynck stands out as a remarkable inventor in the realm of life sciences. His groundbreaking work on adult liver progenitor cells illustrates his dedication to advancing medical research and improving treatment options for liver diseases. His innovations will likely continue to shape the future of regenerative medicine and biotechnology.